CoChat

Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples

Open access
Takemasa · 2010 · International Journal of Oncology

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 2 of the 39 sources its claims cite were checked for support.

Abstract

To improve the prognosis of advanced esophageal cancer, neoadjuvant chemotherapy (NACT) followed by surgery is a promising treatment strategy. NACT has been shown to improve the prognosis of responders. However, non-responders not only suffer from side-effects, but they also lose precious time to take advantage of other possible treatments. Therefore, it is crucial to establish a reliable method that allows prediction of response before chemotherapy. A biopsy sample can provide valuable information on the biological characteristics of an individual esophageal cancer, which can affect chemosensitivity. Comprehensive gene expression profiling (GEP) using oligonucleotide microarray covering 30,000 human probes was performed in 50 pretreatment endoscopic biopsy samples from 25 patients with esophageal squamous cell cancer (ESCC) who underwent cisplatin-based chemotherapy (two samples per patient). Chemotherapeutic responses were evaluated by the reduction rate of the tumor area on CT scans. Responders were defined as patients with reduction rates of ≥50% and non-responders were defined as patients with <50% decrease. The diagnostic system, that predicts responses to chemotherapy, was constructed with the 199 most informative genes, and showed 82% of accuracy. Furthermore, the predictive performance of this system was confirmed using an additional ten samples with an accuracy of 80%. This study shows that GEP of pretreatment ESCC biopsy samples has the potential to predict responses to chemotherapy.

Overview

CoChat Summary

## TL;DR

This study used pretreatment endoscopic biopsy gene-expression profiling to predict response to cisplatin-based chemotherapy in advanced esophageal squamous cell carcinoma (ESCC). A 199-gene diagnostic system achieved 82% accuracy in leave-one-out cross-validation and 80% accuracy in an independent 10-sample validation set.

## Key findings

  • In the estimation set, 50 biopsy samples from 25 patients were profiled; when all 19,166 genes were used, complete leave-one-out cross-validation gave 72% accuracy.
  • After filtering, the authors defined 199 predictive genes (P<0.001 by permutation test); leave-one-out cross-validation with these genes improved accuracy to 82%, with positive predictive value 88.2% (15/17) and negative predictive value 78.8% (26/33).
  • In the independent validation set of 10 patients, the diagnostic system correctly predicted response in 8 of 10 cases (80.0% accuracy), with PPV 75.0% (3/4) and NPV 83.3% (5/6).
  • qRT-PCR on 20 biopsy specimens for five selected genes (PERP, PRDX6, DAD1, SELPINB6, SRF) agreed with the microarray expression patterns.

## Methods

  • Design: observational biomarker study building a gene-expression-based classifier from pretreatment biopsy samples, then testing it in an independent validation set.
  • Data/sample: 50 pretreatment endoscopic biopsy samples from 25 ESCC patients in the estimation set (two samples per patient) and 10 additional pretreatment biopsy samples in the validation set; all patients received cisplatin-based FAP chemotherapy.
  • Analysis: oligonucleotide microarray (30,000 human probes), background correction and filtering, hierarchical cluster analysis, permutation testing to select genes, weighted voting classifier, and leave-one-out cross-validation; qRT-PCR was used to verify five genes.

## Limitations

  • The paper explicitly says the results “warrant validation of the predictive genes with a larger number of patients and eventually in a prospective trial to evaluate its utility.”
  • Evident from the text: the validation set was small (10 patients), so the reported 80% accuracy is based on limited sample size.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3892/ijo_00000763

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Hierarchical cluster analysis with whole genes in 50 biopsy ESCC samples from 25 patients of the estimation set. The rows and columns represent genes and samples, respectively. The color scale at the bottom indicates the relative expression levels in terms of standard deviations from the median. A couple of biopsy samples obtained from the same case were most closely clustered together.
Figure 1 Hierarchical cluster analysis with whole genes in 50 biopsy ESCC samples from 25 patients of the estimation set. The rows and columns represent genes and samples, respectively. The color scale at the bottom indicates the relative expression levels in terms of standard deviations from the median. A couple of biopsy samples obtained from the same case were most closely clustered together.From the PDF
Figure 2 Hierarchical cluster analysis with predictive genes in 50 biopsy ESCC samples from 25 patients of the estimation set. The rows and columns represent genes and samples, respectively. The color scale at the bottom indicates the relative expression levels in terms of standard deviations from the median. The expression patterns of predictive genes showed distinct profiles between the two groups.
Figure 2 Hierarchical cluster analysis with predictive genes in 50 biopsy ESCC samples from 25 patients of the estimation set. The rows and columns represent genes and samples, respectively. The color scale at the bottom indicates the relative expression levels in terms of standard deviations from the median. The expression patterns of predictive genes showed distinct profiles between the two groups.From the PDF
Figure 3 Real-time quantitative RT-PCR expression levels of five genes ( PERP, PRDX6, DAD1, SELPINB6 , and SRF ) in 20 biopsy samples (10 non-responders and 10 responders).
Figure 3 Real-time quantitative RT-PCR expression levels of five genes ( PERP, PRDX6, DAD1, SELPINB6 , and SRF ) in 20 biopsy samples (10 non-responders and 10 responders).From the PDF

Verification

Claims the paper makes

2 Valid · 0 Not valid · 21 Not checked · 39 Own results and interpretations

24 more claims

Create a free account to see all 62 claims and to verify the 6 references still open.

See all claims — free account
  • Probably not a substantial claim. 24
  • It may state two separate claims as one. 13
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Citations

Cites

Cited by

See all 31

Metadata

Authors
Takemasa
Affiliations
The University of Osaka (JP)
Corresponding author
Takemasa
Venue
International Journal of Oncology
Published
2010-09-22
Volume
37
Issue
5
Pages
1113-20
ISSN
  • 1019-6439 (ISSN-L)
  • 1791-2423
OpenAlex
W2146624169
Cited by
31
References
29
Citations by year
2022: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 2 · 2015: 7 · 2014: 3 · 2013: 2 · 2012: 4
FWCI
2.02
Type
journal article
Language
en
Open access
Locations
  • International Journal of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
esophageal squamous cell carcinoma, chemotherapy response prediction, neoadjuvant chemotherapy, cisplatin-based chemotherapy, gene expression profiling, endoscopic biopsy, chemosensitivity, predictive gene signature, tumor shrinkage
MeSH terms
Aged, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Carcinoma, Squamous Cell, Cisplatin, Doxorubicin, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Cluster Analysis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.